Why study sex differences in Alzheimer’s disease and in the context of Down syndrome? The topic of sex differences is increasingly recognized as a top priority in neurology research, particularly in the context of precision medicine and personalized care strategies. Women account for around two-thirds of patients with Alzheimer’s disease, as well as their caregivers. … Read more
Stability of plasma samples and Alzheimer’s biomarkers Alzheimer’s disease is considered one of the most common causes of dementia in the elderly. Recently, blood biomarkers: Aβ1-42, Aβ1-40 and phospho Tau181 (p-Tau181), are proving useful in the diagnosis of the disease in research studies, but their analytical stability is unknown. A joint study between the Memory … Read more
Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, are a growing health concern worldwide, and their diagnosis and management are still challenging. However, recent advances in blood-based biomarkers offer new opportunities for clinical evaluation and monitoring of these diseases. In this review article, entitled “Blood Biomarkers in Neurodegenerative Diseases: Implications for the … Read more
Multimarker panels in FTD Frontotemporal dementia is the most common cause of early-onset dementia and the principal cause of FrontoTemporal Lobular Degeneration (FTLD). Approximately, 90–95% of FTLD cases are characterized by the accumulation in the brain of two different proteins – tau and transactive response DNA-binding protein-43 (TDP-43). These protein inclusions lead to a loss of … Read more
Alzheimer’s disease and its biomarkers in CSF Alzheimer’s disease is a chronic neurodegenerative disorder considered the most common cause of dementia in older people. Although clinical symptoms still form the core of diagnosis, imaging and cerebrospinal fluid biomarkers now play an important role in the diagnostic process. Two important neuropathological features of Alzheimer’s are the … Read more
Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is considered a marker of amyloid pathology, a series of studies have shown that a decrease in CSF Aβ1-42 … Read more